Veracyte Labs SD Corporation

Veracyte Labs SD Corporation, operating as the Decipher Biosciences, Inc. Division, supplies proprietary genomic prostate cancer diagnostic testing services to the Department of Veterans Affairs and the Defense Health Agency as a prime contractor on GSA Schedule 621-II medical laboratory vehicles, competing full-and-open with no set-aside designations.

Veracyte Labs SD is a for-profit subsidiary of Veracyte, Inc., headquartered in South San Francisco, with operations in San Diego, California. The division's sole federal capability centers on the Decipher Prostate Cancer Test, a genomic classifier that analyzes tumor gene expression patterns to assess cancer risk, aggressiveness, and metastatic potential, enabling clinicians to support precision medicine treatment decisions for veteran and military healthcare beneficiaries. All 44 awards in the federal footprint reflect this single, specialized service line — no diversification into other cancer types, allied diagnostics, or ancillary services appears in the award record. The vendor competes exclusively on full-and-open vehicles with no small business set-asides; the specialized and proprietary nature of its genomic testing capabilities has enabled sole-source justifications across multiple contract awards.

Customer concentration sits heavily within the Veterans Health Administration's regional service networks. The top five customers by award count — VISN 17, VISN 21, VISN 1, VISN 8, and VISN 10 — account for 75% of awards (33 of 44). However, the dollar picture diverges sharply: a single award from VISN 12 carries $10.9 million in combined potential value, anchoring 83% of the portfolio's $24.4 million ceiling. VISN 8 ($3.5 million), VISN 1 ($3 million), VISN 21 ($1.4 million), and the VA Strategic Acquisition Center Frederick ($1.3 million) round out the top five by potential value. The Defense Health Agency has placed a smaller footprint — two delivery orders and one IDC worth roughly $340 thousand combined — but represents growth into the military healthcare space beyond VA networks.

Vehicle position is monolithic: 43 task orders sit under the GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), with the remaining awards distributed across three smaller IDCs (36C26120D0064, W81K0224D0013, and BPA 36C25926A0015). The vendor holds five single-award blanket purchase agreements and indefinite delivery contracts as master vehicles: VISN 1 ($1.95 million ceiling, through January 2028), VISN 8 ($972 thousand, through January 2028), VISN 17 ($991 thousand, through November 2026), Defense Health Agency ($194 thousand, through September 2026), and VISN 2 ($486 thousand, through May 2027). Task orders against these masters range from $3,240 to $1.62 million, with recent awards (late 2025 to mid-2026) skewing toward larger delivery orders ($648 thousand to $1.62 million) over smaller BPA calls, suggesting shift toward longer-term, higher-volume commitments.

Activity has grown unevenly: three awards in 2022, nine in 2023, six in 2024, nine in 2025, and five so far in 2026. Eight awards (combined potential value $1.2 million) reach ultimate completion within the next twenty-four months, creating modest recompete exposure. The vendor has obligated only $5.8 million of its $24.4 million combined potential value ceiling (24%), indicating substantial unexercised capacity across existing vehicles, particularly within the two largest master BPAs with VISN 1 and VISN 8. The footprint reflects no subcontractor awards — all 44 awards are prime positions.

NAICS concentration is absolute: 44 awards under Medical Laboratories (NAICS 621511). Primary Service Code work splits across Reference Laboratory Testing (33 awards), Laboratory Equipment and Supplies (5 awards), and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (4 awards), all aligned to the single Decipher test offering. This category depth signals tight market positioning: the vendor is a specialized, sole-source provider with no adjacent service lines, making it a competitive threat only on prostate cancer genomic testing vehicles and a limited teaming opportunity for larger federal IT or systems integrators seeking diagnostic sub-capacity.